Molecular Mechanism Regulating Regeneration of Spinal Nerves Identified
|
By LabMedica International staff writers Posted on 29 Mar 2016 |

Image: A confocal micrograph of the lesion core following spinal cord injury. Nuclear EdU (red) shows the presence of newly differentiated cells which produce Schwann cell myelin (green). These peripheral-like Schwann cells remyelinate central axons in the injured spinal cord and are important for spontaneous repair and functional recovery after spinal cord injury (Photo courtesy of King\'s College London).
The protein neuregulin-1 was found to regulate the repair mechanism that attempts to restore lost myelin following spinal cord injury.
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Latest BioResearch News
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read more
Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
Early identification of individuals with an inherited predisposition to coronary plaque can inform earlier evaluation of coronary artery disease risk, particularly among younger adults who may develop... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more







